Weight loss jabs could have surprise anti-cancer effect
New research suggests that weight loss injections, also known as GLP-1 receptor agonists, may have a significant anti-cancer effect beyond simply aiding in weight reduction.
While experts acknowledge the link between weight loss and reduced cancer risk, this study indicates the injections themselves may play a more direct role.
Researchers believe the anti-cancer properties may stem from the drugs' ability to reduce inflammation, with newer GLP-1 receptor agonists potentially having the most pronounced effect. These medications work by suppressing appetite, making it easier for individuals to lose weight. They are available through the NHS for those with a high BMI and can also be obtained privately.
However, experts caution that further research is crucial to fully understand the relationship between weight loss injections and cancer prevention.
Major names of GLP-1 receptor agonists, some of which are used to treat diabetes, include semaglutide (Wegovy and Ozempic), tirzepatide (Mounjaro), liraglutide (Saxenda) and exenatide (a drug which has now been discontinued).
The new research, published in the journal eClinicalMedicine, was presented at the European Congress on Obesity in Malaga.
It found that first-generation GLP-1 receptor agonists such as liraglutide and exenatide may have anti-cancer benefits beyond weight loss.
Researchers first of all discovered similar rates of obesity-related cancer among patients treated with the drugs and those given bariatric surgery.
Co-lead author, Dr Yael Wolff Sagy from Clalit Health Services in Tel-Aviv, Israel, said they also found a 'direct effect' of GLP-1 receptor agonists beyond weight loss 'to be 41 per cent more effective at preventing obesity-related cancer'.
She added: 'We do not yet fully understand how GLP-1s work, but this study adds to the growing evidence showing that weight loss alone cannot completely account for the metabolic, anti-cancer, and many other benefits that these medications provide.'
Being overweight or obese is the second biggest cause of cancer in the UK, causing more than one in 20 cancer cases.
The risk is higher the more overweight people are and the longer they have been overweight.
Keeping a healthy weight reduces the risk of 13 different types of cancer, including breast, bowel, pancreatic, oesophageal and gallbladder cancer.
In the new study, researchers analysed electronic health record data for obese people and those with type 2 diabetes, all with no prior history of cancer, who were treated with first-generation GLP-1 receptor agonists.
Over a typical follow-up of 7.5 years, 298 patients were diagnosed with obesity-related cancer, most commonly breast, bowel and womb cancer.
The analysis found that obesity-related cancer occurred in 150 of 3,178 bariatric surgery patients and in 148 of 3,178 patients taking GLP-1 receptor agonists, despite the 'relative advantage' of bariatric surgery in weight reduction, which is already known to cut cancer risk.
Further analysis suggested GLP drugs had a direct effect on reducing obesity-related cancer beyond weight loss, with a 41 per cent lower relative risk compared to bariatric surgery.
Co-lead author, Professor Dror Dicker from Hasharon Hospital, Rabin Medical Centre in Israel, said: 'The protective effects of GLP1-RAs against obesity-related cancers likely arise from multiple mechanisms, including reducing inflammation.
'Our study is unique in that the long-term follow-up allowed us to compare the effects of GLP1-RAs and surgery with potential long latency periods of cancer.
'New generation, highly potent GLP1-RAs with higher efficacy in weight reduction may convey an even greater advantage in reducing the risk of obesity-related cancers, but future research is needed to make sure that these drugs do not increase the risk for non-obesity-related cancers.'
Naveed Sattar, professor of cardiometabolic medicine at the University of Glasgow, said larger trials with carefully matched groups of people were needed to test the theory.
'This study, whilst interesting, cannot confirm or refute any links of incretin-based therapies with cancer as the design was not a trial but rather observational, and there were quite marked differences between the groups in baseline characteristics that simply cannot be matched,' he said.
'It is better to wait to see further large outcome trials versus placebo to get closer to the truth.'
He said larger trials 'are needed to understand links between such medicines and cancer risks, and several should report over the next five years'.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
24 minutes ago
- BBC News
BBC Radio Scotland broadcaster Bryan Burnett shares cancer diagnosis with Get it On audience and announces break from programme
BBC Radio Scotland broadcaster Bryan Burnett announced that he will be taking a break from his popular early evening programme Get it On, to undergo treatment for appendiceal cancer. In a short statement Bryan explained that a tumour had been discovered during surgery to remove his appendix earlier this year and that, although appendix cancer is incredibly rare, it is treatable and he is expected to make a full recovery. He went on to say that his treatment will begin next week and involves complex abdominal surgery and chemotherapy. He added that Grant Stott would be stepping in to look after the show in his absence and thanked his colleagues for their support and encouragement since he received the news. Bryan said: 'I've experienced the most incredible care and kindness from the NHS staff who have been looking after me. My surgeon is a Get it On listener so I know I'm in good hands. 'I will really miss the music and the chat when I'm off but our listeners have given me hundreds of great playlists so that will keep me going over the next few months.' Hayley Valentine, director BBC Scotland added: 'Bryan is one of our most popular broadcasters on Radio Scotland and I know listeners will join us in wishing him well as he embarks on his treatment. We look forward to welcoming him back to the Get it On studio once he's recovered.' BBC Scotland Press Office
BBC News
30 minutes ago
- BBC News
BBC Radio Scotland presenter takes break for cancer treatment
BBC Radio Scotland broadcaster Bryan Burnett has announced that he will be taking a break from his programme to undergo treatment for a rare 59, who presents the early evening Get it On show told listeners he was diagnosed with appendiceal cancer after having his appendix removed earlier this said the cancer, while "incredibly rare", is treatable and he is expected to make a full recovery after treatment which will involve complex abdominal surgery and Grant Stott will fill in while Burnett recovers. Get it On is a popular evening show which airs on BBC Radio Scotland from 18:00 on plays requests from listeners which match a theme set each Burnett presented Brand New Country, a country music show on BBC Radio Scotland for 15 years and has had stints on Radio Clyde and Northsound. Surgeon is a Get it On listener "I've experienced the most incredible care and kindness from the NHS staff who have been looking after me. My surgeon is a Get it On listener so I know I'm in good hands," he said."I will really miss the music and the chat when I'm off but our listeners have given me hundreds of great playlists so that will keep me going over the next few months."He delivered the news to his listeners directly in an emotional announcement during his live show on Thursday evening."I want to take this opportunity to say a massive thank you to all my brilliant producers for all the hand holding and all the encouragement they've given me since they found out my news," he said. "I'm sure they'll let you know how I'm doing over the next few weeks". Hayley Valentine, director BBC Scotland said: "Bryan is one of our most popular broadcasters on Radio Scotland and I know listeners will join us in wishing him well as he embarks on his treatment."We look forward to welcoming him back to the Get it On studio once he's recovered."
The Guardian
43 minutes ago
- The Guardian
Weight loss drugs linked to higher risk of eye damage in diabetic patients
Weight loss drugs could at least double the risk of diabetic patients developing age-related macular degeneration, a large-scale study has found. Originally developed for diabetes patients, glucagon-like peptide-1 receptor agonist (GLP-1 RA) medicines have transformed how obesity is treated and there is growing evidence of wider health benefits. They help reduce blood sugar levels, slow digestion and reduce appetite. But a study by Canadian scientists published in Jama Ophthalmology has found that after six months of use GLP-1 RAs are associated with double the risk of older people with diabetes developing neovascular age-related macular degeneration compared with similar patients not taking the drugs. Academics at the University of Toronto examined medical data for more than 1 million Ontario residents with a diagnosis of diabetes and identified 46,334 patients with an average age of 66 who were prescribed GLP-1 RAs. Nearly all (97.5%) were taking semaglutide, while 2.5% were on lixisenatide. The study did not exclude any specific brand of drugs, but since Wegovy was only approved in Canada in November 2021, primarily for weight loss, it is likely the bulk of semaglutide users in the study were taking Ozempic, which is prescribed for diabetes. Each patient on semaglutide or lixisenatide was matched with two patients who also had diabetes but were not taking the drugs, who shared similar characteristics such as age, gender and health conditions. The researchers then compared how many patients developed neovascular age-related macular degeneration over three years. The study found that those who had been taking semaglutide or lixisenatide for at least six months had twice the risk of developing macular degeneration, compared with similar patients who were not taking the drugs. Patients who had been taking GLP-1s for more than 30 months had more than three times the risk. Diabetic patients who were older and/or had had a stroke had an even higher risk of developing macular degeneration if they were on these drugs, the authors found. Marko Popovic, a co-author of the study and physician in the department of ophthalmology and vision sciences at the University of Toronto, said: 'GLP-1 receptor agonists appear to have multiple effects on the eye, and in the case of neovascular age-related macular degeneration the overall impact may be harmful. 'Based on our data, I would advise exercising particular caution when prescribing GLP-1 receptor agonists to older [diabetic] patients or those with a history of stroke, as both groups were found to have an even higher risk of developing [the condition].' In an accompanying editorial, Brian VanderBeek, an associate professor of ophthalmology at the Hospital of the University of Pennsylvania, said the findings suggested that large numbers of patients could be affected. 'This suggests as many as one in 1,000 GLP-1 RA users could progress to new age-related macular degenaration over unexposed patients: if this risk was carried over millions of users, those affected could end up being a sizable group of patients,' he said. VanderBeek said work needed to be done to determine if this only affects patients with diabetes or if those taking these drugs for weight management or other indications are similarly at risk. 'While certainly not outweighing the good these medications offer, prescribing physicians need to keep in mind the real and serious ocular adverse events that may occur.' A spokesperson for Novo Nordisk, which manufactures Ozempic and Wegovy, said: 'Patient safety is our top priority and we take any report about an adverse event related to the use of our medicines very seriously. We work closely with authorities and regulatory bodies from around the world to continuously monitor the safety profile of our products. 'These medicines have been extensively examined in Novo Nordisk's robust clinical development programs, including randomised controlled trials, which to date have not shown any observable treatment difference compared to placebo for macular degeneration or age-related macular degeneration. Therefore, Novo Nordisk does not conclude a causal relationship between GLP-1 RA use, semaglutide and age-related macular degeneration at this time.' Dr Alison Cave, the chief safety officer of the MHRA, a UK watchdog, said: 'Macular degeneration is not currently listed as a potential side-effect of these medicines. However, we keep the safety of these medicines under close review, including emerging evidence from scientific publications, and will take appropriate action where necessary. On the basis of the current evidence, the benefits of GLP-1 RAs outweigh the potential risks when used for the licensed indications.'
